Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 932 drug-target rows in SSL view, for TSG = VHL.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
sunitinib VHL PDGFRA 5
sunitinib VHL FLT3 5
sunitinib VHL MET 5
crizotinib VHL MET 5
bevacizumab VHL VEGFA 3
gemcitabine VHL TYMS 3
srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab VHL TYMS 3
cabozantinib VHL MET 5
capecitabine VHL TYMS 5
everolimus VHL MTOR 5
nintedanib VHL PDGFRA 5
nintedanib VHL FGFR3 5
palbociclib VHL CDK4 5
palbociclib VHL CDK6 5
pazopanib VHL PDGFRA 5
pazopanib VHL FGFR3 5
regorafenib VHL PDGFRA 5
5fu, nab-paclitaxel, bevacizumab, calcium leucovorin, oxaliplatin VHL VEGFA 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib VHL CDK4 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib VHL PDGFRA 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib VHL MAP2K1 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib VHL FGFR3 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib VHL CDK6 2
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib VHL MET 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel VHL MAP2K1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel VHL FGFR3 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel VHL FLT3 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel VHL MET 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel VHL IGF1R 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel VHL TYMS 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine VHL TYMS 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 VHL TYMS 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib VHL CDK4 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib VHL MAP2K1 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib VHL CDK6 2
capecitabine, temozolomide VHL TYMS 2
cft1946, trametinib, cetuximab VHL MAP2K1 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab VHL TYMS 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study VHL IGF1R 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study VHL MTOR 2
cobimetinib, mehd7945a VHL MAP2K1 2
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus VHL MTOR 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab VHL CDK4 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab VHL CDK6 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib VHL FLT3 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide VHL TYMS 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib VHL TYMS 2
jab-3312, binimetinib, pembrolizumab, sotorasib, osimertinib VHL MAP2K1 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate VHL PDGFRA 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate VHL FGFR3 2
mirdametinib, bgb-3245 VHL MAP2K1 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed VHL TYMS 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a VHL PDGFRA 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a VHL FGFR3 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a VHL TYMS 2
motexafin gadolinium, radiation therapy VHL RRM2 2
nab-paclitaxel, gemcitabine VHL TYMS 2
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab VHL PDGFRA 2
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab VHL VEGFA 2
nintedanib VHL FLT3 2
nintedanib, pembrolizumab VHL PDGFRA 2
nintedanib, pembrolizumab VHL FGFR3 2
nintedanib, pembrolizumab VHL FLT3 2
nivolumab, ipilimumab, cobimetinib VHL MAP2K1 2
oleclumab, durvalumab, gemcitabine, nab-paclitaxel, oxaliplatin, folinic acid, 5-fu VHL TYMS 2
osimertinib, bevacizumab, osimertinib VHL VEGFA 2
pd-1 inhibitor, bevacizumab, carboplatin, cisplatin, pemtrexed VHL VEGFA 2
pembrolizumab, guadecitabine, mocetinostat VHL HDAC2 2
pembrolizumab, lenvatinib VHL PDGFRA 2
pembrolizumab, lenvatinib VHL FGFR3 2
pemetrexed, bevacizumab VHL VEGFA 2
pemetrexed, bevacizumab VHL TYMS 2
pharmacological study, romidepsin VHL HDAC2 2
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) VHL PDGFRA 2
regorafenib, laboratory biomarker analysis VHL PDGFRA 2
selumetinib, medi4736, tremelimumab VHL MAP2K1 2
sy-5609, fulvestrant, gemcitabine, nab-paclitaxel VHL TYMS 2
temsirolimus VHL MTOR 2
temsirolimus, laboratory biomarker analysis VHL MTOR 2
tislelizumab, pemetrexed VHL TYMS 2
tivantinib VHL MET 2
whole brain low dose radiotherapy, pemetrexed, sintilimab, chemotherapy VHL TYMS 2
binimetinib VHL MAP2K1 5
pemetrexed VHL TYMS 5
pemigatinib VHL FGFR3 5
ribociclib VHL CDK4 5
ribociclib VHL CDK6 5
romidepsin VHL HDAC2 5
selumetinib VHL MAP2K1 5
sorafenib VHL FLT3 5
trilaciclib VHL CDK4 5
trilaciclib VHL CDK6 5
3-dimensional conformal radiation therapy, bevacizumab, cisplatin, fluorouracil, intensity-modulated radiation therapy VHL VEGFA 1
3-dimensional conformal radiation therapy, bevacizumab, cisplatin, fluorouracil, intensity-modulated radiation therapy VHL TYMS 1
3-dimensional conformal radiation therapy, bevacizumab, intensity-modulated radiation therapy, laboratory biomarker analysis, placebo, quality-of-life assessment, temozolomide VHL VEGFA 1
3-dimensional conformal radiation therapy, biospecimen collection, capecitabine, chemotherapy, computed tomography, erlotinib hydrochloride, fluorouracil, gemcitabine hydrochloride, intensity-modulated radiation therapy, magnetic resonance imaging, quality-of-life assessment, x-ray imaging VHL TYMS 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat VHL HDAC2 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat VHL HDAC2 1
3-dimensional conformal radiation therapy, motexafin gadolinium, temozolomide VHL RRM2 1
4-dimensional computed tomography, fluorouracil, gemcitabine hydrochloride, laboratory biomarker analysis, leucovorin calcium, nelfinavir mesylate, oregovomab, stereotactic body radiation therapy, therapeutic conventional surgery VHL TYMS 1
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin VHL VEGFA 1
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin VHL TYMS 1
6,8-bis(benzylthio)octanoic acid, oxaliplatin, leucovorin calcium, irinotecan hydrochloride, fluorouracil, laboratory biomarker analysis VHL TYMS 1
7-hydroxystaurosporine, fluorouracil VHL TYMS 1
9-ing-41, retifanlimab, gemcitabine, abraxane VHL TYMS 1
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine VHL VEGFA 1
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine VHL TYMS 1
abemaciclib, abemaciclib VHL CDK4 1
abemaciclib, abemaciclib VHL CDK6 1
abemaciclib, bevacizumab VHL CDK4 1
abemaciclib, bevacizumab VHL CDK6 1
abemaciclib, bevacizumab VHL VEGFA 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf VHL CDK4 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf VHL CDK6 1
abemaciclib, ly3023414, gemcitabine, capecitabine VHL CDK4 1
abemaciclib, ly3023414, gemcitabine, capecitabine VHL CDK6 1
abemaciclib, ly3023414, gemcitabine, capecitabine VHL TYMS 1
abemaciclib, ly3214996 VHL CDK4 1
abemaciclib, ly3214996 VHL CDK6 1
abemaciclib, surgery VHL CDK4 1
abemaciclib, surgery VHL CDK6 1
abraxane (nab-paclitaxel), gemcitabine VHL TYMS 1
adct-601, gemcitabine VHL TYMS 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy VHL HDAC2 1
adriamycin, cyclophosphamide, vindesine, valproic acid VHL HDAC2 1
aee788, everolimus VHL MTOR 1
afatinib dimaleate, capecitabine, laboratory biomarker analysis VHL TYMS 1
afatinib, dasatinib, palbociclib, everolimus, olaparib VHL CDK4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib VHL CDK6 1
afatinib, dasatinib, palbociclib, everolimus, olaparib VHL MTOR 1
ag-013736, gemcitabine, gemcitabine, placebo VHL TYMS 1
agen1423, botensilimab, gemcitabine, nab-paclitaxel VHL TYMS 1
ags-1c4d4, gemcitabine VHL TYMS 1
ak104, ak104, gemcitabine, nab-paclitaxel VHL TYMS 1
ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, nab-paclitaxel, gemcitabine, nab-paclitaxel, gemcitabine VHL TYMS 1
akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib VHL MAP2K1 1
akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib VHL TYMS 1
albumin-bound paclitaxel (abi-007), gemcitabine VHL TYMS 1
aldesleukin, antibody therapy, fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, laboratory biomarker analysis, leucovorin calcium, oxaliplatin, paclitaxel albumin-stabilized nanoparticle formulation, sargramostim VHL TYMS 1
alisertib, gemcitabine VHL TYMS 1
alpelisib, everolimus, exemestane VHL MTOR 1
alvocidib, docetaxel VHL CDK4 1
alvocidib, docetaxel VHL CDK6 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis VHL CDK4 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis VHL CDK6 1
amg 193, gemcitabine, nab-paclitaxel, modified folfirinox VHL TYMS 1
amg 479, placebo, amg 479, gemcitabine VHL TYMS 1
amgen 386, bevacizumab VHL VEGFA 1
amivantamab VHL MET 1
andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel VHL VEGFA 1
andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel VHL TYMS 1
anetumab ravtansine, bevacizumab, paclitaxel VHL VEGFA 1
ang1005, bevacizumab VHL VEGFA 1
anti-endoglin chimeric monoclonal antibody trc105, bevacizumab, laboratory biomarker analysis, pharmacological study, quality-of-life assessment VHL VEGFA 1
apg-1387 for injection, gemcitabine, nab paclitaxel VHL TYMS 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib VHL CDK4 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib VHL CDK6 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib VHL MTOR 1
aprepitant, gemcitabine hydrochloride, capecitabine, fluorouracil, radiation therapy, questionnaire administration, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications VHL TYMS 1
apx005m, nivolumab, nab-paclitaxel, gemcitabine VHL TYMS 1
arq 197, gemcitabine VHL TYMS 1
asc40 tablets, placebo tablets, bevacizumab VHL VEGFA 1
ascorbate, nab paclitaxel, gemcitabine VHL TYMS 1
ascorbic acid, paclitaxel protein-bound, cisplatin, gemcitabine VHL TYMS 1
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan VHL TYMS 1
atezolizumab injection, bevacizumab, transarterial chemoembolization VHL VEGFA 1
atezolizumab, bevacizumab VHL VEGFA 1
atezolizumab, bevacizumab, laboratory biomarker analysis, pharmacological study VHL VEGFA 1
atezolizumab, cabozantinib VHL MET 1
atezolizumab, tivozanib VHL PDGFRA 1
atezolizumab, tivozanib VHL FLT3 1
atezolizumab, tivozanib VHL MET 1
atorvastatin, temozolomide, radiotherapy VHL HDAC2 1
atra, gemcitabine, nab-paclitaxel VHL TYMS 1
avastin (bevacizumab), gemcitabine, radiation therapy VHL TYMS 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab VHL HDAC2 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab VHL TYMS 1
azd0171, durvalumab, gemcitabine, nab-paclitaxel VHL TYMS 1
azd0901, 5-fluorouracil, leucovorin, l-leucovorin, irinotecan, nanoliposomal irinotecan, gemcitabine VHL TYMS 1
azd1775, gemcitabine, nab-paclitaxel VHL TYMS 1
azd5335, saruparib (azd5305), bevacizumab, carboplatin VHL VEGFA 1
azd6244, dacarbazine, erlotinib, docetaxel, temsirolimus VHL MTOR 1
bbi608, nab-paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, fluorouracil, mm-398 VHL TYMS 1
bethanechol, gemcitabine, nab-paclitaxel VHL TYMS 1
bevacizumab, bevacizumab VHL VEGFA 1
bevacizumab, biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, osimertinib VHL VEGFA 1
bevacizumab, biospecimen collection, computed tomography, electronic health record review, hypofractionated radiation therapy, magnetic resonance imaging, retifanlimab VHL VEGFA 1
bevacizumab, bkm120 VHL VEGFA 1
bevacizumab, capecitabine, gemcitabine hydrochloride VHL VEGFA 1
bevacizumab, capecitabine, gemcitabine hydrochloride VHL TYMS 1
bevacizumab, capecitabine/oxaliplatin, fluorouracil/folinic acid/oxaliplatin, capecitabine, fluorouracil/folinic acid/irinotecan, fluorouracil +/- folinic acid VHL VEGFA 1
bevacizumab, capecitabine/oxaliplatin, fluorouracil/folinic acid/oxaliplatin, capecitabine, fluorouracil/folinic acid/irinotecan, fluorouracil +/- folinic acid VHL TYMS 1
bevacizumab, carmustine VHL VEGFA 1
bevacizumab, cediranib maleate VHL VEGFA 1
bevacizumab, cediranib, cediranib maleate, olaparib VHL VEGFA 1
bevacizumab, chemotherapy, fractionated radiosurgery VHL VEGFA 1
bevacizumab, chest radiation, concurrent chemotherapy VHL VEGFA 1
bevacizumab, cisplatin, etoposide, radiation therapy VHL VEGFA 1
bevacizumab, cisplatin, gemcitabine hydrochloride VHL VEGFA 1
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment VHL VEGFA 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.